{"transactions":[{"id":885561,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2026-02-24T23:14:46.000Z","date":"2026-02-23","kind":"exercise","planned":false,"acquired":false,"shares":6688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":36357,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6688},"source":{"system":"sec-edgar","filing":"0001159036-26-000029","document":"wk-form4_1771974883.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000029/wk-form4_1771974883.xml","form_type":"4"}},{"id":885560,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-02-24T23:14:46.000Z","date":"2026-02-20","kind":"exercise","planned":false,"acquired":false,"shares":5332,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":15995,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5332},"source":{"system":"sec-edgar","filing":"0001159036-26-000029","document":"wk-form4_1771974883.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000029/wk-form4_1771974883.xml","form_type":"4"}},{"id":885559,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-24T23:14:46.000Z","date":"2026-02-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":3608,"price":70.64,"value":254869.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition of 3,608 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":38494,"source":{"system":"sec-edgar","filing":"0001159036-26-000029","document":"wk-form4_1771974883.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000029/wk-form4_1771974883.xml","form_type":"4"}},{"id":885558,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-24T23:14:46.000Z","date":"2026-02-23","kind":"exercise","planned":false,"acquired":true,"shares":6688,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":42102,"source":{"system":"sec-edgar","filing":"0001159036-26-000029","document":"wk-form4_1771974883.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000029/wk-form4_1771974883.xml","form_type":"4"}},{"id":885557,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-24T23:14:46.000Z","date":"2026-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":2876,"price":70.98,"value":204138.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":35414,"source":{"system":"sec-edgar","filing":"0001159036-26-000029","document":"wk-form4_1771974883.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000029/wk-form4_1771974883.xml","form_type":"4"}},{"id":885556,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-24T23:14:46.000Z","date":"2026-02-20","kind":"exercise","planned":false,"acquired":true,"shares":5332,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":38290,"source":{"system":"sec-edgar","filing":"0001159036-26-000029","document":"wk-form4_1771974883.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000029/wk-form4_1771974883.xml","form_type":"4"}},{"id":901668,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2026-02-17T23:52:46.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":false,"shares":13351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13351},"source":{"system":"sec-edgar","filing":"0001159036-26-000026","document":"wk-form4_1771372364.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000026/wk-form4_1771372364.xml","form_type":"4"}},{"id":901667,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-02-17T23:52:46.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":false,"shares":5329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":5329,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5329},"source":{"system":"sec-edgar","filing":"0001159036-26-000026","document":"wk-form4_1771372364.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000026/wk-form4_1771372364.xml","form_type":"4"}},{"id":901666,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-02-17T23:52:46.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":false,"shares":5093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5093},"source":{"system":"sec-edgar","filing":"0001159036-26-000026","document":"wk-form4_1771372364.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000026/wk-form4_1771372364.xml","form_type":"4"}},{"id":901665,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-17T23:52:46.000Z","date":"2026-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":7273,"price":79.44,"value":577767.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported disposition of 7,273 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":32958,"source":{"system":"sec-edgar","filing":"0001159036-26-000026","document":"wk-form4_1771372364.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000026/wk-form4_1771372364.xml","form_type":"4"}},{"id":901664,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-17T23:52:46.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":true,"shares":13351,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":40231,"source":{"system":"sec-edgar","filing":"0001159036-26-000026","document":"wk-form4_1771372364.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000026/wk-form4_1771372364.xml","form_type":"4"}},{"id":901663,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-17T23:52:46.000Z","date":"2026-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2874,"price":79.44,"value":228310.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition of 2,874 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":26880,"source":{"system":"sec-edgar","filing":"0001159036-26-000026","document":"wk-form4_1771372364.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000026/wk-form4_1771372364.xml","form_type":"4"}},{"id":901662,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-17T23:52:46.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":true,"shares":5329,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":29754,"source":{"system":"sec-edgar","filing":"0001159036-26-000026","document":"wk-form4_1771372364.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000026/wk-form4_1771372364.xml","form_type":"4"}},{"id":901661,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-17T23:52:46.000Z","date":"2026-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2747,"price":79.44,"value":218221.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,747 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":24425,"source":{"system":"sec-edgar","filing":"0001159036-26-000026","document":"wk-form4_1771372364.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000026/wk-form4_1771372364.xml","form_type":"4"}},{"id":901660,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-17T23:52:46.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":true,"shares":5093,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":27172,"source":{"system":"sec-edgar","filing":"0001159036-26-000026","document":"wk-form4_1771372364.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000026/wk-form4_1771372364.xml","form_type":"4"}},{"id":910286,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2026-02-12T02:20:34.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":29502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":29502,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":29502},"source":{"system":"sec-edgar","filing":"0001159036-26-000015","document":"wk-form4_1770862831.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000015/wk-form4_1770862831.xml","form_type":"4"}},{"id":910285,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2026-02-12T02:20:34.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":7448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":43045,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7448},"source":{"system":"sec-edgar","filing":"0001159036-26-000015","document":"wk-form4_1770862831.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000015/wk-form4_1770862831.xml","form_type":"4"}},{"id":910284,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2026-02-12T02:20:34.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":5167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":13351,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5167},"source":{"system":"sec-edgar","filing":"0001159036-26-000015","document":"wk-form4_1770862831.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000015/wk-form4_1770862831.xml","form_type":"4"}},{"id":1033905,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-09-23T20:15:01.000Z","date":"2025-09-22","kind":"sale","planned":true,"acquired":false,"shares":314,"price":78.667,"value":24701.438,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $78.37 to $79.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22079,"source":{"system":"sec-edgar","filing":"0001910662-25-000003","document":"form4-09232025_080958.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000191066225000003/form4-09232025_080958.xml","form_type":"4"}},{"id":1033904,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-09-23T20:15:01.000Z","date":"2025-09-22","kind":"sale","planned":true,"acquired":false,"shares":1913,"price":77.827,"value":148883.051,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $77.34 to $78.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":22393,"source":{"system":"sec-edgar","filing":"0001910662-25-000003","document":"form4-09232025_080958.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000191066225000003/form4-09232025_080958.xml","form_type":"4"}},{"id":1043122,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2025-09-11T21:09:57.000Z","date":"2025-09-10","kind":"exercise","planned":true,"acquired":false,"shares":1135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on August 1, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":812,"derivative":{"exercise_price":12.49,"expiration_date":"2027-08-01","underlying":"Common Stock","underlying_shares":1135},"source":{"system":"sec-edgar","filing":"0001415889-25-024295","document":"form4-09112025_090953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925024295/form4-09112025_090953.xml","form_type":"4"}},{"id":1043121,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2025-09-11T21:09:57.000Z","date":"2025-09-10","kind":"exercise","planned":true,"acquired":false,"shares":11271,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":11271},"source":{"system":"sec-edgar","filing":"0001415889-25-024295","document":"form4-09112025_090953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925024295/form4-09112025_090953.xml","form_type":"4"}},{"id":1043120,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-09-11T21:09:57.000Z","date":"2025-09-10","kind":"sale","planned":true,"acquired":false,"shares":13240,"price":75.929,"value":1005299.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $75.56 to $76.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":24306,"source":{"system":"sec-edgar","filing":"0001415889-25-024295","document":"form4-09112025_090953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925024295/form4-09112025_090953.xml","form_type":"4"}},{"id":1043119,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-09-11T21:09:57.000Z","date":"2025-09-10","kind":"sale","planned":true,"acquired":false,"shares":6760,"price":75.291,"value":508967.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $74.56 to $75.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":37546,"source":{"system":"sec-edgar","filing":"0001415889-25-024295","document":"form4-09112025_090953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925024295/form4-09112025_090953.xml","form_type":"4"}},{"id":1043118,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-09-11T21:09:57.000Z","date":"2025-09-10","kind":"exercise","planned":true,"acquired":true,"shares":1135,"price":12.49,"value":14176.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."}],"balance_after":44306,"source":{"system":"sec-edgar","filing":"0001415889-25-024295","document":"form4-09112025_090953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925024295/form4-09112025_090953.xml","form_type":"4"}},{"id":1043117,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-09-11T21:09:57.000Z","date":"2025-09-10","kind":"exercise","planned":true,"acquired":true,"shares":11271,"price":12.07,"value":136040.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025."}],"balance_after":43171,"source":{"system":"sec-edgar","filing":"0001415889-25-024295","document":"form4-09112025_090953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925024295/form4-09112025_090953.xml","form_type":"4"}},{"id":1250101,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-24T22:04:21.000Z","date":"2025-02-23","kind":"exercise","planned":false,"acquired":false,"shares":6688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":20063,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6688},"source":{"system":"sec-edgar","filing":"0001415889-25-005299","document":"form4-02242025_100217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005299/form4-02242025_100217.xml","form_type":"4"}},{"id":1250100,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-24T22:04:21.000Z","date":"2025-02-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":3601,"price":57.75,"value":207957.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 3,601 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":31900,"source":{"system":"sec-edgar","filing":"0001415889-25-005299","document":"form4-02242025_100217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005299/form4-02242025_100217.xml","form_type":"4"}},{"id":1250099,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-24T22:04:21.000Z","date":"2025-02-23","kind":"exercise","planned":false,"acquired":true,"shares":6688,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":35501,"source":{"system":"sec-edgar","filing":"0001415889-25-005299","document":"form4-02242025_100217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005299/form4-02242025_100217.xml","form_type":"4"}},{"id":1253552,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-21T23:49:01.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":21327,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":21327,"derivative":{"exercise_price":0,"exercise_date":"2026-02-20","underlying":"Common Stock","underlying_shares":21327},"source":{"system":"sec-edgar","filing":"0001415889-25-005173","document":"form4-02212025_110257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005173/form4-02212025_110257.xml","form_type":"4"}},{"id":1253551,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2025-02-21T23:49:01.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":22603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":22603,"derivative":{"exercise_price":57.44,"exercise_date":"2026-02-20","expiration_date":"2035-02-20","underlying":"Common Stock","underlying_shares":22603},"source":{"system":"sec-edgar","filing":"0001415889-25-005173","document":"form4-02212025_110257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005173/form4-02212025_110257.xml","form_type":"4"}},{"id":1264529,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T23:39:13.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":false,"shares":5329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":10658,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5329},"source":{"system":"sec-edgar","filing":"0001415889-25-004507","document":"form4-02182025_110210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004507/form4-02182025_110210.xml","form_type":"4"}},{"id":1264528,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T23:39:13.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":false,"shares":5093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":5093,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5093},"source":{"system":"sec-edgar","filing":"0001415889-25-004507","document":"form4-02182025_110210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004507/form4-02182025_110210.xml","form_type":"4"}},{"id":1264527,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2025-02-18T23:39:13.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":false,"shares":17409,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":17409},"source":{"system":"sec-edgar","filing":"0001415889-25-004507","document":"form4-02182025_110210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004507/form4-02182025_110210.xml","form_type":"4"}},{"id":1264526,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T23:39:13.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":false,"shares":1254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1254},"source":{"system":"sec-edgar","filing":"0001415889-25-004507","document":"form4-02182025_110210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004507/form4-02182025_110210.xml","form_type":"4"}},{"id":1264525,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:39:13.000Z","date":"2025-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2869,"price":58.29,"value":167234.01,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The reported disposition of 2,869 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":28813,"source":{"system":"sec-edgar","filing":"0001415889-25-004507","document":"form4-02182025_110210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004507/form4-02182025_110210.xml","form_type":"4"}},{"id":1264524,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:39:13.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":true,"shares":5329,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":31682,"source":{"system":"sec-edgar","filing":"0001415889-25-004507","document":"form4-02182025_110210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004507/form4-02182025_110210.xml","form_type":"4"}},{"id":1264523,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:39:13.000Z","date":"2025-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2742,"price":58.29,"value":159831.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported disposition of 2,742 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":26353,"source":{"system":"sec-edgar","filing":"0001415889-25-004507","document":"form4-02182025_110210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004507/form4-02182025_110210.xml","form_type":"4"}},{"id":1264522,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:39:13.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":true,"shares":5093,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":29095,"source":{"system":"sec-edgar","filing":"0001415889-25-004507","document":"form4-02182025_110210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004507/form4-02182025_110210.xml","form_type":"4"}},{"id":1264521,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:39:13.000Z","date":"2025-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":9400,"price":58.29,"value":547926.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition of 9,400 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":24002,"source":{"system":"sec-edgar","filing":"0001415889-25-004507","document":"form4-02182025_110210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004507/form4-02182025_110210.xml","form_type":"4"}},{"id":1264520,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:39:13.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":true,"shares":17409,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":33402,"source":{"system":"sec-edgar","filing":"0001415889-25-004507","document":"form4-02182025_110210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004507/form4-02182025_110210.xml","form_type":"4"}},{"id":1264519,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:39:13.000Z","date":"2025-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":741,"price":58.29,"value":43192.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 741 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":15993,"source":{"system":"sec-edgar","filing":"0001415889-25-004507","document":"form4-02182025_110210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004507/form4-02182025_110210.xml","form_type":"4"}},{"id":1264518,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:39:13.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":true,"shares":1254,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16734,"source":{"system":"sec-edgar","filing":"0001415889-25-004507","document":"form4-02182025_110210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004507/form4-02182025_110210.xml","form_type":"4"}},{"id":1267863,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2025-02-14T23:09:43.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":28662,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":28662,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":28662},"source":{"system":"sec-edgar","filing":"0001415889-25-004237","document":"form4-02142025_110239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004237/form4-02142025_110239.xml","form_type":"4"}},{"id":1267862,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Performance Stock Unit","published_at":"2025-02-14T23:09:43.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":6935,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":6935,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6935},"source":{"system":"sec-edgar","filing":"0001415889-25-004237","document":"form4-02142025_110239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004237/form4-02142025_110239.xml","form_type":"4"}},{"id":1267861,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2025-02-14T23:09:43.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":5221,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2023 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2023 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":8184,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5221},"source":{"system":"sec-edgar","filing":"0001415889-25-004237","document":"form4-02142025_110239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004237/form4-02142025_110239.xml","form_type":"4"}},{"id":1267860,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2025-02-14T23:09:43.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":6050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2022 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2022 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":17409,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6050},"source":{"system":"sec-edgar","filing":"0001415889-25-004237","document":"form4-02142025_110239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004237/form4-02142025_110239.xml","form_type":"4"}},{"id":1450054,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-07-23T20:37:10.000Z","date":"2024-07-22","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on July 1, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":22.5,"expiration_date":"2025-07-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-24-019936","document":"form4-07232024_080706.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924019936/form4-07232024_080706.xml","form_type":"4"}},{"id":1450053,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-23T20:37:10.000Z","date":"2024-07-22","kind":"sale","planned":true,"acquired":false,"shares":992,"price":54.253,"value":53818.976,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $54.17 to $54.325. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15480,"source":{"system":"sec-edgar","filing":"0001415889-24-019936","document":"form4-07232024_080706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924019936/form4-07232024_080706.xml","form_type":"4"}},{"id":1450052,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-23T20:37:10.000Z","date":"2024-07-22","kind":"exercise","planned":true,"acquired":true,"shares":992,"price":22.5,"value":22320.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."}],"balance_after":16472,"source":{"system":"sec-edgar","filing":"0001415889-24-019936","document":"form4-07232024_080706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924019936/form4-07232024_080706.xml","form_type":"4"}},{"id":1450051,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-23T20:37:10.000Z","date":"2024-07-22","kind":"sale","planned":true,"acquired":false,"shares":4008,"price":53.853,"value":215842.824,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $53.17 to $54.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15480,"source":{"system":"sec-edgar","filing":"0001415889-24-019936","document":"form4-07232024_080706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924019936/form4-07232024_080706.xml","form_type":"4"}},{"id":1450050,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-23T20:37:10.000Z","date":"2024-07-22","kind":"exercise","planned":true,"acquired":true,"shares":4008,"price":22.5,"value":90180.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."}],"balance_after":19488,"source":{"system":"sec-edgar","filing":"0001415889-24-019936","document":"form4-07232024_080706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924019936/form4-07232024_080706.xml","form_type":"4"}},{"id":1467489,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-06-28T20:06:56.000Z","date":"2024-06-28","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on July 1, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":5000,"derivative":{"exercise_price":22.5,"expiration_date":"2025-07-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-018408","document":"form4-06282024_080653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924018408/form4-06282024_080653.xml","form_type":"4"}},{"id":1467488,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-06-28T20:06:56.000Z","date":"2024-06-27","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on July 1, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":15000,"derivative":{"exercise_price":22.5,"expiration_date":"2025-07-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-018408","document":"form4-06282024_080653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924018408/form4-06282024_080653.xml","form_type":"4"}},{"id":1467487,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-06-28T20:06:56.000Z","date":"2024-06-26","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on July 1, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":25000,"derivative":{"exercise_price":22.5,"expiration_date":"2025-07-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-018408","document":"form4-06282024_080653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924018408/form4-06282024_080653.xml","form_type":"4"}},{"id":1467486,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-28T20:06:56.000Z","date":"2024-06-28","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":52.04,"value":520400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $51.52 to $52.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15480,"source":{"system":"sec-edgar","filing":"0001415889-24-018408","document":"form4-06282024_080653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924018408/form4-06282024_080653.xml","form_type":"4"}},{"id":1467485,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-28T20:06:56.000Z","date":"2024-06-28","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":22.5,"value":225000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."}],"balance_after":25480,"source":{"system":"sec-edgar","filing":"0001415889-24-018408","document":"form4-06282024_080653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924018408/form4-06282024_080653.xml","form_type":"4"}},{"id":1467484,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-28T20:06:56.000Z","date":"2024-06-27","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":51.934,"value":519340.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $51.66 to $52.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15480,"source":{"system":"sec-edgar","filing":"0001415889-24-018408","document":"form4-06282024_080653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924018408/form4-06282024_080653.xml","form_type":"4"}},{"id":1467483,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-28T20:06:56.000Z","date":"2024-06-27","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":22.5,"value":225000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."}],"balance_after":25480,"source":{"system":"sec-edgar","filing":"0001415889-24-018408","document":"form4-06282024_080653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924018408/form4-06282024_080653.xml","form_type":"4"}},{"id":1467482,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-28T20:06:56.000Z","date":"2024-06-26","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":51.82,"value":518200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $51.605 to $52.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15480,"source":{"system":"sec-edgar","filing":"0001415889-24-018408","document":"form4-06282024_080653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924018408/form4-06282024_080653.xml","form_type":"4"}},{"id":1467481,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-28T20:06:56.000Z","date":"2024-06-26","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":22.5,"value":225000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024."}],"balance_after":25480,"source":{"system":"sec-edgar","filing":"0001415889-24-018408","document":"form4-06282024_080653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924018408/form4-06282024_080653.xml","form_type":"4"}},{"id":1616464,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2024-02-27T22:05:35.000Z","date":"2024-02-23","kind":"grant","planned":false,"acquired":true,"shares":26751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":26751,"derivative":{"exercise_price":0,"exercise_date":"2025-02-23","underlying":"Common Stock","underlying_shares":26751},"source":{"system":"sec-edgar","filing":"0001415889-24-005539","document":"form4-02272024_100224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924005539/form4-02272024_100224.xml","form_type":"4"}},{"id":1616463,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-27T22:05:35.000Z","date":"2024-02-23","kind":"grant","planned":false,"acquired":true,"shares":27722,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":27722,"derivative":{"exercise_price":40.56,"exercise_date":"2025-02-23","expiration_date":"2034-02-23","underlying":"Common Stock","underlying_shares":27722},"source":{"system":"sec-edgar","filing":"0001415889-24-005539","document":"form4-02272024_100224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924005539/form4-02272024_100224.xml","form_type":"4"}},{"id":1634613,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2024-02-20T23:53:11.000Z","date":"2024-02-16","kind":"exercise","planned":false,"acquired":false,"shares":5329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":15987,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5329},"source":{"system":"sec-edgar","filing":"0001415889-24-004475","document":"form4-02202024_110227.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004475/form4-02202024_110227.xml","form_type":"4"}},{"id":1634612,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2024-02-20T23:53:11.000Z","date":"2024-02-16","kind":"exercise","planned":false,"acquired":false,"shares":5093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":10186,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5093},"source":{"system":"sec-edgar","filing":"0001415889-24-004475","document":"form4-02202024_110227.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004475/form4-02202024_110227.xml","form_type":"4"}},{"id":1634611,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-20T23:53:11.000Z","date":"2024-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2864,"price":36.1,"value":103390.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition of 2,864 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":15480,"source":{"system":"sec-edgar","filing":"0001415889-24-004475","document":"form4-02202024_110227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004475/form4-02202024_110227.xml","form_type":"4"}},{"id":1634610,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-20T23:53:11.000Z","date":"2024-02-16","kind":"exercise","planned":false,"acquired":true,"shares":5329,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18344,"source":{"system":"sec-edgar","filing":"0001415889-24-004475","document":"form4-02202024_110227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004475/form4-02202024_110227.xml","form_type":"4"}},{"id":1634609,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-20T23:53:11.000Z","date":"2024-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2737,"price":36.1,"value":98805.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,737 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":13015,"source":{"system":"sec-edgar","filing":"0001415889-24-004475","document":"form4-02202024_110227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004475/form4-02202024_110227.xml","form_type":"4"}},{"id":1634608,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-20T23:53:11.000Z","date":"2024-02-16","kind":"exercise","planned":false,"acquired":true,"shares":5093,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15752,"source":{"system":"sec-edgar","filing":"0001415889-24-004475","document":"form4-02202024_110227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004475/form4-02202024_110227.xml","form_type":"4"}},{"id":1638753,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2024-02-16T22:41:51.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":false,"shares":1254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":1254,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1254},"source":{"system":"sec-edgar","filing":"0001415889-24-004185","document":"form4-02162024_100244.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004185/form4-02162024_100244.xml","form_type":"4"}},{"id":1638752,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-16T22:41:51.000Z","date":"2024-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":686,"price":35.91,"value":24634.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 686 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":10659,"source":{"system":"sec-edgar","filing":"0001415889-24-004185","document":"form4-02162024_100244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004185/form4-02162024_100244.xml","form_type":"4"}},{"id":1638751,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-16T22:41:51.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":true,"shares":1254,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11345,"source":{"system":"sec-edgar","filing":"0001415889-24-004185","document":"form4-02162024_100244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004185/form4-02162024_100244.xml","form_type":"4"}},{"id":1646700,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2024-02-13T21:15:51.000Z","date":"2024-02-10","kind":"exercise","planned":false,"acquired":false,"shares":2502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2502},"source":{"system":"sec-edgar","filing":"0001415889-24-003525","document":"form4-02132024_090242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924003525/form4-02132024_090242.xml","form_type":"4"}},{"id":1646699,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-13T21:15:51.000Z","date":"2024-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":1477,"price":35.49,"value":52418.73,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 1,477 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":10091,"source":{"system":"sec-edgar","filing":"0001415889-24-003525","document":"form4-02132024_090242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924003525/form4-02132024_090242.xml","form_type":"4"}},{"id":1646698,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-13T21:15:51.000Z","date":"2024-02-10","kind":"exercise","planned":false,"acquired":true,"shares":2502,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11568,"source":{"system":"sec-edgar","filing":"0001415889-24-003525","document":"form4-02132024_090242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924003525/form4-02132024_090242.xml","form_type":"4"}},{"id":2004001,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2023-02-22T00:00:58.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":21316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":21316,"derivative":{"exercise_price":0,"exercise_date":"2024-02-16","underlying":"Common Stock","underlying_shares":21316},"source":{"system":"sec-edgar","filing":"0001415889-23-002954","document":"form4-02222023_120245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002954/form4-02222023_120245.xml","form_type":"4"}},{"id":2004000,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2023-02-22T00:00:58.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":61061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":61061,"derivative":{"exercise_price":49.26,"exercise_date":"2024-02-16","expiration_date":"2033-02-16","underlying":"Common Stock","underlying_shares":61061},"source":{"system":"sec-edgar","filing":"0001415889-23-002954","document":"form4-02222023_120245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002954/form4-02222023_120245.xml","form_type":"4"}},{"id":2003999,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2023-02-22T00:00:58.000Z","date":"2023-02-16","kind":"exercise","acquired":false,"shares":5094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":15279,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5094},"source":{"system":"sec-edgar","filing":"0001415889-23-002954","document":"form4-02222023_120245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002954/form4-02222023_120245.xml","form_type":"4"}},{"id":2003998,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-02-22T00:00:58.000Z","date":"2023-02-16","kind":"sale","acquired":false,"shares":2525,"price":49.26,"value":124381.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,525 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":9066,"source":{"system":"sec-edgar","filing":"0001415889-23-002954","document":"form4-02222023_120245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002954/form4-02222023_120245.xml","form_type":"4"}},{"id":2003997,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-02-22T00:00:58.000Z","date":"2023-02-16","kind":"exercise","acquired":true,"shares":5094,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11591,"source":{"system":"sec-edgar","filing":"0001415889-23-002954","document":"form4-02222023_120245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002954/form4-02222023_120245.xml","form_type":"4"}},{"id":2008224,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2023-02-17T11:25:29.000Z","date":"2023-02-15","kind":"exercise","acquired":false,"shares":1254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":2508,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1254},"source":{"system":"sec-edgar","filing":"0001415889-23-002712","document":"form4-02172023_110222.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002712/form4-02172023_110222.xml","form_type":"4"}},{"id":2008223,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-02-17T11:25:29.000Z","date":"2023-02-15","kind":"tax_withholding","acquired":false,"shares":621,"price":49.2,"value":30553.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 621 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":6497,"source":{"system":"sec-edgar","filing":"0001415889-23-002712","document":"form4-02172023_110222.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002712/form4-02172023_110222.xml","form_type":"4"}},{"id":2008222,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-02-17T11:25:29.000Z","date":"2023-02-15","kind":"exercise","acquired":true,"shares":1254,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7118,"source":{"system":"sec-edgar","filing":"0001415889-23-002712","document":"form4-02172023_110222.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002712/form4-02172023_110222.xml","form_type":"4"}},{"id":2017047,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2023-02-14T22:21:01.000Z","date":"2023-02-12","kind":"exercise","acquired":false,"shares":1389,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1389},"source":{"system":"sec-edgar","filing":"0001415889-23-002511","document":"form4-02142023_100247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002511/form4-02142023_100247.xml","form_type":"4"}},{"id":2017046,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2023-02-14T22:21:01.000Z","date":"2023-02-10","kind":"exercise","acquired":false,"shares":2503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":2502,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2503},"source":{"system":"sec-edgar","filing":"0001415889-23-002511","document":"form4-02142023_100247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002511/form4-02142023_100247.xml","form_type":"4"}},{"id":2017045,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-02-14T22:21:01.000Z","date":"2023-02-12","kind":"tax_withholding","acquired":false,"shares":681,"price":48.92,"value":33314.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition of 681 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":5864,"source":{"system":"sec-edgar","filing":"0001415889-23-002511","document":"form4-02142023_100247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002511/form4-02142023_100247.xml","form_type":"4"}},{"id":2017044,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-02-14T22:21:01.000Z","date":"2023-02-12","kind":"exercise","acquired":true,"shares":1389,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6545,"source":{"system":"sec-edgar","filing":"0001415889-23-002511","document":"form4-02142023_100247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002511/form4-02142023_100247.xml","form_type":"4"}},{"id":2017043,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-02-14T22:21:01.000Z","date":"2023-02-10","kind":"tax_withholding","acquired":false,"shares":1392,"price":48.92,"value":68096.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 1,392 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":5156,"source":{"system":"sec-edgar","filing":"0001415889-23-002511","document":"form4-02142023_100247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002511/form4-02142023_100247.xml","form_type":"4"}},{"id":2017042,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-02-14T22:21:01.000Z","date":"2023-02-10","kind":"exercise","acquired":true,"shares":2503,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6548,"source":{"system":"sec-edgar","filing":"0001415889-23-002511","document":"form4-02142023_100247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588923002511/form4-02142023_100247.xml","form_type":"4"}},{"id":2114857,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-11-17T00:51:07.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":365,"price":53.69,"value":19596.85,"ownership":{"direct":true},"balance_after":4045,"source":{"system":"sec-edgar","filing":"0001415889-22-011459","document":"form4-11172022_121159.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588922011459/form4-11172022_121159.xml","form_type":"4"}},{"id":2114856,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-11-17T00:51:07.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":4635,"price":53.82,"value":249455.7,"ownership":{"direct":true},"balance_after":4410,"source":{"system":"sec-edgar","filing":"0001415889-22-011459","document":"form4-11172022_121159.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588922011459/form4-11172022_121159.xml","form_type":"4"}},{"id":2388980,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-17T23:03:40.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":20373,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter."}],"balance_after":20373,"derivative":{"exercise_price":0,"exercise_date":"2023-02-16","underlying":"Common Stock","underlying_shares":20373},"source":{"system":"sec-edgar","filing":"0001179110-22-001393","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022001393/edgar.xml","form_type":"4"}},{"id":2388979,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2022-02-17T23:03:40.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":62315,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":62315,"derivative":{"exercise_price":34.36,"exercise_date":"2023-02-16","expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":62315},"source":{"system":"sec-edgar","filing":"0001179110-22-001393","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022001393/edgar.xml","form_type":"4"}},{"id":2388978,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-17T23:03:40.000Z","date":"2022-02-15","kind":"exercise","acquired":false,"shares":1255,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":3762,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1255},"source":{"system":"sec-edgar","filing":"0001179110-22-001393","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022001393/edgar.xml","form_type":"4"}},{"id":2388977,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-17T23:03:40.000Z","date":"2022-02-15","kind":"tax_withholding","acquired":false,"shares":433,"price":34.43,"value":14908.19,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 433 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":9045,"source":{"system":"sec-edgar","filing":"0001179110-22-001393","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022001393/edgar.xml","form_type":"4"}},{"id":2388976,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-17T23:03:40.000Z","date":"2022-02-15","kind":"exercise","acquired":true,"shares":1255,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9478,"source":{"system":"sec-edgar","filing":"0001179110-22-001393","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022001393/edgar.xml","form_type":"4"}},{"id":2398629,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-02-15T00:28:45.000Z","date":"2022-02-14","kind":"exercise","acquired":false,"shares":1256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1256},"source":{"system":"sec-edgar","filing":"0001179110-22-001200","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022001200/edgar.xml","form_type":"4"}},{"id":2398628,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-15T00:28:45.000Z","date":"2022-02-12","kind":"exercise","acquired":false,"shares":1389,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":1389,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1389},"source":{"system":"sec-edgar","filing":"0001179110-22-001200","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022001200/edgar.xml","form_type":"4"}},{"id":2398627,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-15T00:28:45.000Z","date":"2022-02-10","kind":"exercise","acquired":false,"shares":2503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":5005,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2503},"source":{"system":"sec-edgar","filing":"0001179110-22-001200","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022001200/edgar.xml","form_type":"4"}},{"id":2398626,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":64998,"kind":"person","name":"LaBrosse Nicole","position":1,"cik":"0001910662","reported_name":"LaBrosse Nicole","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-15T00:28:45.000Z","date":"2022-02-14","kind":"tax_withholding","acquired":false,"shares":427,"price":33.64,"value":14364.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported disposition of 427 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":8223,"source":{"system":"sec-edgar","filing":"0001179110-22-001200","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911022001200/edgar.xml","form_type":"4"}}],"next_cursor":"2022-02-15T00:28:45.000000Z,2398626"}